<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="98963">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01680458</url>
  </required_header>
  <id_info>
    <org_study_id>A0561022</org_study_id>
    <nct_id>NCT01680458</nct_id>
  </id_info>
  <brief_title>Diflucan Research For Infant Evaluation Of Antifungal Treatment And Prophylaxis Medication</brief_title>
  <acronym>DREAM</acronym>
  <official_title>Special Investigation Of Diflucan For Infant Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To collect the efficacy and safety information of fluconazole on infant subjects related to
      their appropriate use in daily practice.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) by Seriousness and Relationship to Treatment</measure>
    <time_frame>13 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinical Response of Cure at the Test-of-Cure (TOC) Visit</measure>
    <time_frame>13 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Deep Mycosis</condition>
  <arm_group>
    <arm_group_label>fluconazole</arm_group_label>
    <description>Infant Subjects who are treated with fluconazole</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluconazole</intervention_name>
    <description>Candidiasis infection: The recommended dosage in children is 3 mg/kg once daily.
Cryptococcal infection: The recommended dosage in children is 6 mg/kg once daily. A dosage of 12 mg/kg once daily may be used, based on medical judgment of the patient's response to therapy.
Prophylactic administration for deep mycosis on Hematopoietic stem cell transplantation: The recommended dosage in children is 12 mg/kg once daily.
Absolute doses exceeding 600 mg/day are not recommended.</description>
    <arm_group_label>fluconazole</arm_group_label>
    <other_name>Diflucan</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The patients whom an investigator involving A0561022 prescribes the fluconazole
        (Diflucan).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or Female under age of seven patients who are prescribed fluconazole (Diflucan)
             for antifungal treatment or prophylaxis administration.

        Exclusion Criteria:

          -  Subject of seven years or more who have been prescribed fluconazole.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0561022&amp;StudyName=Diflucan%20Research%20For%20Infant%20Evaluation%20Of%20Antifungal%20Treatment%20And%20Prophylaxis%20Medication</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 12, 2014</lastchanged_date>
  <firstreceived_date>September 4, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>antifungal treatment</keyword>
  <keyword>prophylaxis</keyword>
  <keyword>administration</keyword>
  <keyword>Japanese</keyword>
  <keyword>infants</keyword>
  <keyword>fluconazole</keyword>
  <keyword>Diflucan</keyword>
  <keyword>Regulatory Post Marketing Commitment Plan.</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mycoses</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antifungal Agents</mesh_term>
    <mesh_term>Fluconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
